Atozet 10/40 mg or 10/80 mg + Lipitor 40 mg or 80 mg
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease
Trial Timeline
Jul 26, 2023 → Oct 15, 2024
NCT ID
NCT05761444About Atozet 10/40 mg or 10/80 mg + Lipitor 40 mg or 80 mg
Atozet 10/40 mg or 10/80 mg + Lipitor 40 mg or 80 mg is a approved stage product being developed by Organon for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05761444. Target conditions include Atherosclerotic Cardiovascular Disease.
What happened to similar drugs?
7 of 20 similar drugs in Atherosclerotic Cardiovascular Disease were approved
Approved (7) Terminated (0) Active (13)
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05761444 | Approved | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease